Dr. John P. Donoghue Presents on Cyberkinetics' BrainGate System in "Smart Prosthetics" Symposium at the AAAS Annual Meeting in San Francisco.

FOXBOROUGH, Mass. -- Cyberkinetics Neurotechnology Systems, Inc. (OTCBB:CYKN; "Cyberkinetics") announced that John P. Donoghue, Ph.D., Cyberkinetics' Chief Scientific Officer, discussed the rapidly expanding field of neuroprosthetics in a symposium entitled "Smart Prosthetics: Interfaces to the Nervous System Help Restore Independence" at the annual meeting of the American Association for the Advancement of Science (AAAS) on Friday, February 16, 2007, in San Francisco, California. The AAAS is an international scientific society dedicated to advancing science throughout the world. In his presentation entitled, "Interfaces to the Brain for Control," Dr. Donoghue provided an overview of brain-computer interfaces, such as Cyberkinetics' BrainGate System, that enable direct communication between the brain and external devices, including computers and even wheelchairs.

"With the recent advances in neuroscience, engineering, computer science and medicine, we are designing prosthetic technologies to 'repair' a person's nervous system," stated Dr. Donoghue. "We are already working on a system that we believe could ultimately enable paralyzed people to use their own muscles to feed themselves - or even walk - allowing them to lead more independent lives."

Dr. Donoghue, along with symposium organizer, Hunter Peckham, Ph.D., Donnell Professor of Biomedical Engineering and Orthopedics at Case Western Reserve University (Case), are working with Cyberkinetics and the Cleveland FES (Functional Electrical Stimulation) Center, to develop a neuroprosthetic system capable restoring partial arm and hand function to people with severe paralysis due to spinal cord injury (SCI). The joint project combines the limb-movement technology developed at Case and the FES Center with Cyberkinetics' BrainGate neural interface technology. The five-year project is being funded by the National Center for Medical Rehabilitation Research (NCMRR), a component of the National Institute of Child Health and Human Development (NICHD).

A founder of Cyberkinetics and a world-recognized leader in the research and development of neural prosthetics and brain-computer interfaces, Dr. Donoghue is the Henry Merritt Wriston Professor and Director of the Brain Science Program at Brown University.

About Cyberkinetics Neurotechnology Systems, Inc.

Cyberkinetics Neurotechnology Systems, Inc., a leader in the neurotechnology industry, is developing neural stimulation, sensing and processing technology to improve the lives of those with severe paralysis resulting from spinal cord injuries, neurological disorders and other conditions of the nervous system. Cyberkinetics' product development pipeline includes: the Andara[TM] OFS[TM] Device, an investigative device designed to stimulate nerve repair and restore sensation and motor function following recent nerve injuries; the BrainGate System, an investigative device designed to provide communication and control of a computer, assistive devices, and, ultimately, limb movement; and a pilot program in the detection and prediction of seizures due to Epilepsy. Additional information is available at Cyberkinetics' website at http://www.cyberkineticsinc.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including statements about Cyberkinetics' product development plans and progress. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and can be identified by the use of forward-looking terminology such as "may," "will," "believe," "expect," "anticipate" or other comparable terminology. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected in forward-looking statements and reported results shall not be considered an indication of our future performance. Factors that might cause or contribute to such differences include our limited operating history; our lack of profits from operations; our ability to successfully develop and commercialize our proposed products; a lengthy approval process and the uncertainty of FDA and other governmental regulatory requirements; clinical trials may fail to demonstrate the safety and effectiveness of our products; the degree and nature of our competition; our ability to employ and retain qualified employees; compliance with recent legislation regarding corporate governance, including the Sarbanes-Oxley Act of 2002; as well as those risks more fully discussed in our public filings with the Securities and Exchange Commission, all of which are difficult to predict and some of which are beyond our control.